Meng MA of risk of tapering MTX from combo with bDMARD/tsDMARD in RA in remission. RR 0.90 (95% CI 0.84, 0.97) for maintaining remission over maximum 18 months. Authors conclude little risk to stopping - I disagree 10% is >0. @RheumNow #ACR22 Abstr#0916 https://t.co/9lJXdeVmpg https://t.co/CEV29Mc8uW